Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
Joseph Slattery serves on our board of directors. Mr. Slattery currently serves on the board of directors of Replimune, Morphic Therapeutic and CVRx, Inc. He previously served as executive vice president and CFO of TransEnterix, Inc., as executive vice president and CFO at Baxano Surgical Inc., and as CFO and senior vice president of finance and information systems of Digene Corp. He has served on the board of directors of Micromet, Inc., TranS1, Inc., and Exosome Diagnostics, Inc. Our management team’s efforts to seek a suitable business combination target will be complemented and augmented by the team members’ expertise and network of relationships. Having selected Boston as Omega’s headquarters early on in its foundation and its strategic relationship with NeoMed, with offices in Geneva, Switzerland, and Oslo, Norway, we believe we will have a transatlantic presence and network of relationships in North America and Europe that will allow us to generate an attractive transaction for our shareholders.
This record is keyed to SEC CIK 0001246530 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 59 institutional-holder rows on these vehicles, under 28 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.